By Digifin Pty Ltd · About this coverage
Key Points
- Australian stimulated-cycle market contracted by 3.2% in Q1 FY27 relative to Q4 FY26
- 12 month rolling market share of 19.4%, broadly in line with 30 June 2026
- Transformation program targeted to deliver $8-11 million annualised pre-tax savings
- No quantitative FY27 earnings guidance; further update due with half year results

About Monash IVF (ASX:MVF)
Monash IVF Group Limited is an ASX-listed provider of assisted reproductive services headquartered in Melbourne. It operates fertility clinics, day hospitals, genetics and diagnostic laboratories and women's imaging services in Australia, and also has clinics in Malaysia and Singapore. Its services include in vitro fertilisation, donor programs and preimplantation genetic testing.
Monash IVF (ASX:MVF) released this trading update to warn that it expects underlying FY27 NPAT to be materially below FY26 and current analyst consensus estimates, citing cost pressures and softer volumes.
Relative to Q4 FY26, the Australian stimulated-cycle market contracted by 3.2% in Q1 FY27. The company's 12 month rolling market share of 19.4% was broadly in line with its share at 30 June 2026, with share lost in South Australia due to new local competitive pressures. It reports fixed cost increases above inflation, largely in occupancy, wages and insurance premiums, above inflation price increases from some key suppliers, and commissioning losses on new capacity in Queensland day surgery and WA ultrasound. Its Brisbane operations were temporarily closed for approximately one month in July 2026 during the move to a new facility. The structural productivity transformation program remains targeted to deliver $8-11 million annualised pre-tax savings, but earnings benefits are now expected over a longer period than previously anticipated. Depreciation and interest expenses are expected to be higher than FY26. The company says trading in October and November delivered improved earnings performance against Q1 FY27.
The outlook assumes market activity does not improve in H2 FY27. The Board does not consider there is a sufficiently reliable basis for quantitative FY27 earnings guidance, and the figures are unaudited. A further update is planned with the half year results.
Source: Monash IVF Group Limited (ASX:MVF), 20 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.
